Results 141 to 150 of about 93,221 (259)

Conditional survival in glioblastoma: The evolution of prognostic factors over time

International Journal of Cancer, Volume 158, Issue 10, Page 2571-2580, 15 May 2026.
What's New? Neurooncologists rely on glioblastoma risk stratification systems for incorporating known disease‐ and patient‐specific factors at diagnosis. Although useful for general comparison and disease monitoring, these estimates are less informative for patients who survive beyond various time intervals post‐diagnosis.
Timothy Mueller, Flavio Vasella, Julia Velz, Stefanos Voglis, Kevin Akeret, Luis Padevit, Morton Schubert, Jonathan Weller, Sarah Brüningk, Elisabeth Rushing, Johannes Sarnthein, Dorothee Gramatzki, Levin Häni, Andreas Raabe, Anna M. Zeitlberger, Oliver Bozinov, Emilie Le Rhun, Michael Weller, Luca Regli, Marian C. Neidert   +19 more
wiley   +1 more source

Patient derived xenograft models of small-cell lung cancer provide molecular insights into mechanisms of chemotherapy cross-resistance [PDF]

, 2018
Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a 5% survival rate over 5 years. Though SCLC comprises 13% of all cases of lung cancer the median survival time of 14.5 months has seen little improvement over the last four ...
Myers, David Thomas
core  

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death

Cell Death Discovery
Glioblastoma is an incurable brain tumor with a median survival below two years. Trials investigating targeted therapy with inhibitors of the kinase mTOR have produced ambiguous results.
Benedikt Sauer, Nadja I. Lorenz, Iris Divé, Kevin Klann, Anna-Luisa Luger, Hans Urban, Jan-Hendrik Schröder, Joachim P. Steinbach, Christian Münch, Michael W. Ronellenfitsch   +9 more
doaj   +1 more source

ABCB1 Polymorphisms Influence on Temozolomide Resistance and Overall Survival in Glioblastoma Patients: A Systematic Review of Clinical Evidence. [PDF]

J Cell Mol Med
ABSTRACT Glioblastoma (GB), defined as IDH‐wildtype CNS WHO grade 4 tumour according to the 2021 WHO classification of CNS tumours, remains a uniformly lethal malignancy in which the efficacy of temozolomide (TMZ) continues to be constrained by both intrinsic tumur biology and the pharmacological barrier imposed by the blood–brain barrier (BBB).
De Luca F, Mannino D, Capra AP, Ciappina G, Donato M, Caruso G, Esposito E, Ardizzone A.   +7 more
europepmc   +2 more sources

Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

Journal of Translational Medicine
Background In the fight against GBM, drug repurposing emerges as a viable and time-saving approach to explore new treatment options. Chlorpromazine, an old antipsychotic medication, has recently arisen as a promising candidate for repositioning in GBM ...
Paola Matarrese, Michele Signore, Barbara Ascione, Giulia Fanelli, Marco G. Paggi, Claudia Abbruzzese   +5 more
doaj   +1 more source

MET fusions and splicing variants in glioma: a landscape integrating clinical, pathological, and survival features

The Journal of Pathology: Clinical Research, Volume 12, Issue 3, May 2026.
Abstract MET alterations, including MET fusions and splicing variants (F/SVs), are linked to glioma progression, but the clinical features remain underexplored since the 2021 WHO classification of tumors of the CNS. We aimed to systematically depict the MET F/SVs and patient characteristics in a multicenter cohort focusing on clinical, pathological ...
Zheng Fang, Chengjun Zheng, Peng Wang, Xing Liu, Lingyu Liu, Guanzhang Li, Jiahan Dong, Qiaodong Chen, Delong Zhang, Yutong Feng, Ying Zhang, Zhaoshi Bao   +11 more
wiley   +1 more source

Application progress of temozolomide in clinical tumor chemotherapy

Chinese Journal of Contemporary Neurology and Neurosurgery, 2013
Temozolomide is an imidazotetrazine derivative of the alkylating agent, which is used to treat central nervous system tumors, especially malignant brain gliomas. It is a milestone in brain giloma chemotherapy. Recently, some researchers used temozolomide
Cheng ZHONG, Bin WANG, Sheng-qing LV
doaj  

Severe Occupational Hypersensitivity Pneumonitis: A Case Series of Four Patients Requiring Lung Transplantation

American Journal of Industrial Medicine, Volume 69, Issue 5, Page 323-334, May 2026.
ABSTRACT Hypersensitivity pneumonitis (HP) is an immune‐mediated interstitial lung disease triggered by repeated inhalation of organic or chemical antigens. Occupational exposures account for approximately 19% of all cases. Early diagnosis, identification of the responsible antigen(s), and immediate avoidance of exposure are crucial to prevent ...
Ludwig Frei‐Stuber, Judith Mohren, Ester Mau, Bernhard Werner, Rudolf A. Hatz, Jürgen Barton, Dennis Nowak   +6 more
wiley   +1 more source